Be the first to like.

Share

The legislation, from House Energy and Commerce Committee Chairman Greg Walden (R-Ore.), is more limited than an earlier measure championed by Sen. Ron Johnson (R-Wis.) that passed the Senate last fall. Walden’s version would ensure that the Food and Drug Administration has more oversight of the process. Like the Senate bill, it includes liability protections for drug companies and providers who decide to use the process. Walden’s bill also limits the process to patients who are likely to die “within a matter of months” or “severely premature.”

In a statement, Walden and health subcommittee chairman Michael Burgess (R-Tex.) said they believe the legislation is now ready for a vote in the House of Representatives.

… Read More

Be the first to like.

Share
STAT

Tags: , , , , , , , , , , , ,

Leave a Reply